Cediranib Shows Promise for Differentiated Thyroid Cancer

TUESDAY, Sept. 19, 2023 -- The multitargeted tyrosine kinase inhibitor (TKI) of the vascular endothelial growth factor receptor (VEGFR) pathway, cediranib, shows promise for differentiated thyroid cancer (DTC), but the addition of lenalidomide to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news